Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Vascular normalization is an emerging concept in cancer treatment. In this issue, Rolny et al show that histidine-rich glycoprotein normalizes tumor vessels and promotes anti-tumor immunity - by polarizing tumor-associated macrophages - leading to decreased tumor growth and metastasis. Placental Growth Factor deletion in macrophages phenocopies many of these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“This positive feedback in the normalized tumor microenvironment may confer an additional advantage: extended window of normalization compared to Cancer Cell blockade of VEGF signaling alone (Jain, 2005; Winkler et al., 2004).”
BackgroundMethodSelf-citationNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Self-citationRolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 12×
“Indeed, the deletion of PlGF in macrophages phenocopied anti-tumor and vascular normalization effects of HRG treatment (Rolny et al., 2011).”
BackgroundInfluential
Cited by
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
“Within breast cancer lesions, TAMs represent the dominant myeloid cell population and usually have an immunosuppressiveM2-like phenotype associated with the hypoxic tumor microenvironment (14, 17, 18).”
BackgroundSelf-citationVascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
“Conversely, M2-like TAMs express high level of arginase (Arg)1, IL-10, VEGF and transforming growth factor (TGF)-β which suppress Th1 T cell immunity (10, 17).”
Self-citationImproving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Self-citationRadiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Sung, Y.-C., Jin, P.-R., Chu, L.-A., Hsu, F.-F., Wang, M.-R., Chang, C.-C., Chiou, S.-J., Qiu, J. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 452
Metadata
- Authors
- Huang, Y., Snuderl, M., & Jain, R. K.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 1-2
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2006833192
- Cited by
- 100
- References
- 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.